Related Experiment Video

Updated: Jun 6, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Adverse dermatologic effects of erdafitinib in a patient with metastatic urothelial carcinoma

Megan Johnson1, Marie Clark2, Carli Whittington2,3

  • 1Indiana University School of Medicine, Indianapolis, IN, USA.

Dermatology Online Journal
|June 5, 2026
PubMed

Insights

Erdafitinib, a FGFR inhibitor, can cause rare nail toxicity called onychomadesis in urothelial carcinoma patients. Early dermatologic care is crucial for managing this side effect and continuing treatment.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Erdafitinib is a targeted therapy for advanced urothelial carcinoma.
  • Cutaneous side effects are common, with nail changes frequently reported.
  • Onychomadesis is a less common but potentially disruptive nail toxicity associated with erdafitinib.
Keywords:
erdafitinibnailsoncologyonychomadesistherapeutics

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...